First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Journal of Clinical Medicine · 13.05.2026 · 15 (10) · 3747
DOI: 10.3390/jcm15103747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.05.2026. Verfasst von Paul Widmann-Sedlnitzky und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME.
Methods
We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid.
Results
Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN.
Conclusions
First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria.
- Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria.
- Carl Zeiss Meditec AG, 73447 Oberkochen, Germany.
ORCID-Profile: Paul Widmann-Sedlnitzky, Kim Lien Huber, Heiko Stino, Andreas Pollreisz
Zitieren
APA
Widmann-Sedlnitzky, P., Huber, K. L., Steiner, I., Stino, H., Kunze, L., Schmoll, T., Gerendas, B. S., Kriechbaum, K., Sacu, S., & Pollreisz, A. (2026). First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria. Journal of Clinical Medicine, 15(10), 3747. https://doi.org/10.3390/jcm15103747
Vancouver
Widmann-Sedlnitzky P, Huber KL, Steiner I, Stino H, Kunze L, Schmoll T, et al. First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria. Journal of Clinical Medicine. 2026;15(10):3747. doi:10.3390/jcm15103747
BibTeX
@article{WidmannSedlnitzky2026,
author = {Widmann-Sedlnitzky, Paul and Huber, Kim Lien and Steiner, Irene and Stino, Heiko and Kunze, Laura and Schmoll, Tilman and Gerendas, Bianca S and Kriechbaum, Katharina and Sacu, Stefan and Pollreisz, Andreas},
title = {First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {10},
pages = {3747},
doi = {10.3390/jcm15103747}
}
EUVIMED